Longevity Startups

MitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.

4 investors

Muna Therapeutics is a biotechnology company that discovers and develops therapies aimed at slowing or stopping neurodegenerative diseases, including Alzheimer's and Parkinson's. It operates in neurology-focused drug discovery and development.

4 investors

NRG Therapeutics is a clinical-stage neuroscience drug discovery company developing disease-modifying, oral small-molecule medicines that target mitochondrial function via inhibition of the mitochondrial permeability transition pore. Its pipeline addresses neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS/MND) and Parkinson's, with lead candidate NRG5051 entering a first-in-human trial.

4 investors

Nucleus provides genetic testing and analysis for couples planning pregnancy, screening for over 200 hereditary diseases, traits, and health conditions. For those undergoing IVF, the company offers embryo selection guidance to reduce disease risk and optimize traits including eye color, height, and intelligence.

4 investors

Rejuvenate Bio is a biotechnology company developing gene therapies aimed at treating age-related diseases, with a pipeline that includes a canine mitral valve disease (MVD) program. It focuses on longevity and aging-related therapeutics.

4 investors

Viome offers at-home tests that analyze the gut and oral microbiome plus cellular blood samples using mRNA/metatranscriptomic sequencing, returning 70+ health scores (including biological age and inflammation) and personalized food and supplement recommendations. The direct-to-consumer service, analyzed in a CLIA-certified lab, is aimed at individuals seeking insights into digestion, metabolism, and overall wellness.

4 investors

VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs. It backs early-stage research projects and companies working on drug discovery and interventions to extend human healthspan and lifespan.

4 investors

PURMX Therapeutics develops nucleic acid medicines as anti-cancer drugs based on microRNA research and the concept of an "ageing switch" to induce ageing in cancer cells. The Japanese pharmaceutical venture handles drug development functions including non-clinical research, clinical development, CMC, and regulatory affairs.

4 investors

Ageless is a Japanese startup providing recruitment and staffing services mainly for the middle-aged and senior workforce. It aims to remove age-related barriers so people can remain economically active regardless of age, addressing Japan's aging population challenges.

3 investors

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that inhibit hunger to treat metabolic diseases. Its lead compound, ARD-101, is an oral investigational drug for hunger-associated rare diseases that activates bitter taste receptors in the gut to trigger satiety signals, with potential applications in hyperphagia and obesity.

3 investors

Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.

3 investors

BIOIO develops a genetics-based platform for elucidating drug mechanisms of action, combining decades of research in pharmacology with big data and automation to accelerate drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to understand how drugs work.

3 investors

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The therapies use modified blood stem cells to restore function of affected genes and offer potential cures rather than symptom management.

3 investors

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria. Its pipeline includes a first-in-class mitophagy agonist intended for therapeutic use in aging- and disease-related conditions.

3 investors

Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration. The company applies translational biology and drug development expertise across multiple therapeutic areas.

3 investors

Centenara Labs is a longevity-focused drug discovery company that translates research on the biology of aging into therapies intended to improve healthy aging and extend lifespan. It works with a global team drawn from medical and scientific institutions to develop longevity drugs and related technologies.

3 investors

Cleara Biotech is a biopharmaceutical R&D company developing peptide-based therapies that selectively eliminate cells with impaired p53 signaling, targeting cancer and chronic diseases. Its lead development candidates, CL04177 and CL04183, aim to induce apoptosis in cancer cells with mutant or impaired p53, with preclinical work in metastatic colon cancer and triple-negative breast cancer.

3 investors

ConcertoCare provides coordinated in-home and center-based medical, behavioral, and social care for seniors and adults with complex care needs who have Medicare, Medicare Advantage, or Medicare+Medicaid coverage. As a risk-bearing provider, it uses proprietary care pathways, analytics, and virtual care technology while working alongside patients' existing doctors and benefit plans.

3 investors

Death Clock is a longevity platform that gives users a life expectancy estimate based on clinical studies and provides personalized health plans built on bloodwork from Quest and Labcorp lab tests. It targets consumers worldwide seeking to extend healthy lifespan through data-driven recommendations curated by doctors.

3 investors

Deep Longevity develops AI-powered aging clocks that predict biological age using blood, DNA, microbiome, and behavioral data to provide personalized health insights and recommendations. The company offers SaaS platforms (SenoClock and SenoClock Gold) to healthcare providers and enterprises for generating biological age predictions and health reports.

3 investors

Elixir Therapeutics develops therapies for rare diseases and aging-related conditions using proprietary technologies, including ZSCAN4 for telomere extension in stem cell therapies and Bobcat mRNA for delivering large genes. The company is advancing clinical candidates for telomere biology disorders and Duchenne muscular dystrophy.

3 investors

Elysium develops healthcare products focused on aging research and healthy aging rather than disease treatment. The company translates aging research into accessible solutions for individuals seeking to improve their long-term health outcomes.

3 investors

Felix is a Canadian digital healthcare platform offering online diagnosis, treatment, and prescription for everyday health needs such as weight loss, mental health, and sexual health. It provides at-home, on-demand care for patients across Canada.

3 investors

HarborSite develops a targeted gene insertion platform that engineers site-specific recombinase enzymes to integrate therapeutic genes into safe genomic sites. It aims to create one-time, durable treatments for genetic and age-associated diseases.

3 investors